Login
$VYGR
$1.63 -$0.10 (5.78%) Live

$VYGR 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Completion of Acquisition or Disposition of Assets

- VY7523 clinical data readout on track for Q4 2026 and VY1706 dosing expected in the next few months pending enrollment -

21 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Amended and Restated Employment Agreement (this “Agreement”) is made as of October 20, 2026 (the “Effective Date”) by and between Voyager Therapeutics, Inc. (the “Company”) and Robin Swartz (the “Executive”).

06 Aug 2026 8-K: Results of Operations and Financial Condition

- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -

13 Jul 2026 8-K: Other Events

On July 13, 2026, Voyager Therapeutics, Inc. (the “Company”) presented good laboratory practice (“GLP”) toxicology data for VY1706, the Company’s investigational tau silencing gene therapy developed to target intracellular and extracellu...

10 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders

Voyager Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, does hereby certify as follows:

01 Jun 2026 8-K: Other Events

On June 1, 2026, Voyager Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for VY1706, the Company’s investigational tau silencing gene therapy de...

07 May 2026 8-K: Results of Operations and Financial Condition

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 -

21 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 15, 2026, Nathan Jorgensen, Ph.D. notified Voyager Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the C...

09 Mar 2026 8-K: Results of Operations and Financial Condition

- Transformative year for tau in AD: VY1706 clinical entry and VY7523 clinical data anticipated H2 2026 -

12 Feb 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

08 Jan 2026 8-K: Regulation FD Disclosure

Leveraging Genetics to Treat Neurological Diseases Corporate Deck / January 2026

10 Nov 2025 8-K: Results of Operations and Financial Condition

- Momentum building around tau: expect VY7523 clinical data and VY1706 clinical entry in 2026 -

02 Sep 2025 8-K: Regulation FD Disclosure

Leveraging Genetics to Treat Neurological Diseases Citi 2025 Biopharma Back to School Conference September 2, 2025

06 Aug 2025 8-K: Results of Operations and Financial Condition

- Cash runway extended into 2028; expected to enable multiple meaningful clinical data read-outs -

05 Jun 2025 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

At the annual meeting of stockholders of Voyager Therapeutics, Inc. (“Voyager”) held on June 3, 2025 (the “2025 Annual Meeting”), Voyager’s stockholders approved the 2025 Stock Incentive Plan (the “2025 Stock Incentive Plan”) and the Ame...

06 May 2025 8-K: Results of Operations and Financial Condition

- Tau silencing gene therapy VY1706 to be featured in oral presentation at ASGCT 2025; has shown up to 73% knockdown of tau mRNA in the CNS in NHPs following a single IV dose of 1.3e13 vg/kg -

11 Mar 2025 8-K: Results of Operations and Financial Condition

- Tau silencing gene therapy VY1706 robustly reduced tau mRNA levels, with broad distribution, and was well-tolerated in NHP study; IND filing anticipated in 2026 -

11 Feb 2025 8-K: Other Events

On February 11, 2025, Voyager Therapeutics, Inc. (the “Company”) announced that it has decided to assess alternate payloads related to its superoxide dismutase 1 silencing gene therapy program for amyotrophic lateral sclerosis (the “SOD1...

12 Nov 2024 8-K: Results of Operations and Financial Condition

–Enrollment and dosing complete in single ascending dose clinical trial of anti-tau antibody VY7523 for Alzheimer’s; on track to generate top-line data H1 2025–

05 Sep 2024 8-K: Entry into a Material Definitive Agreement

Amendment to Option and License Agreement with Novartis Pharma AG

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support